Pediatr. praxi. 2007;8(6):363-368

Pneumococcal diseases in pediatric clinical practice

doc. MUDr. Hana Houšťková CSc3, MUDr. Vítězslav Dedek CSc1, prof. MUDr. Karel Křepela CSc3, MUDr. Martin Fajt2, MUDr. Jindřich Pohl3
1 Dětská klinika I. LF UK a IPVZ, Fakultní Thomayrova nemocnice, Praha
2 JIRP, Pediatrická klinika 1. LF a IPVZ, Fakultní Thomayerova nemocnice, Praha
3 Pediatrická klinika 1. LF UK a IPVZ ve FTNsP, Praha

Streptococcus pneumoniae became the most important bacterial pathogenic microorganism, especially in children under 5 years. Due to its specific characteristics it causes numerous invasive disorders with serious prognosis. Case reports document clinical symptoms and the course of severe pneumococcal infections. Various aspects of clinical symptoms are discussed, especially diagnostic facilities, therapy and prevention of infection induced by Streptococcus pneumoniae.

Keywords: Streptococcus pneumoniae, invasive disorders, prevention

Published: January 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Houšťková H, Dedek V, Křepela K, Fajt M, Pohl J. Pneumococcal diseases in pediatric clinical practice. Pediatr. praxi. 2007;8(6):363-368.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Behrman, RE, Kliegman, RM, Jenson, HB. Nelson textbook of pediatrics, 17th Edition, 2004.
    2. Bingen E, Levy C. Pneumococcal meningitis in France: age and medical risk factors in children. Arch Pediatr. 2005; 12(7): 1187-1189. Go to original source... Go to PubMed...
    3. Buckingham SC, McCullers JA et al. Early Vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics 2006; 117(5): 1688-1694. Go to original source... Go to PubMed...
    4. Casado-Flores J, Aristegui J et al. Clinical data and factors associated with poor outcome in pneumococcal meningitis. Eur.J.Pediatr, 2006; 165(5): 285-289. Go to original source... Go to PubMed...
    5. Davis LE. Pneumococcal meningitis: antibiotics essential but insufficient. Brain. 2003; 126, 1013-1014. Go to original source... Go to PubMed...
    6. Grijalva CG, Nuorti E et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369: 1179-1186. Go to original source... Go to PubMed...
    7. Koedel U, Scheld WM et al. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2: 721-736. Go to original source... Go to PubMed...
    8. Macintosh ED. Treatment and prevention strategies to combat pediatric pneumococcal meningitis. Expert Rev.Anti.Infect.Ther. 2005; 3(5): 739-750. Go to original source... Go to PubMed...
    9. McIntyre PB, MacIntyre CR et al. A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis, Arch. Dis. Child. 2005; 90: 391-396. Go to original source... Go to PubMed...
    10. Neumann MI, Harper MB. Evaluation of a rapid urine antigen assay for the detection of invasive pneumococcal disease in children. Pediatrics 2003; 112: 1279-1282. Go to original source... Go to PubMed...
    11. Ostergaard C, Hoiby N et al. Prehospital diagnostic and therapeutic management of otogenic Streptococcus pneumoniae meningitis. Scand J Infect Dis. 2006; 38(3): 172-180. Go to original source... Go to PubMed...
    12. Ozen M, Kanra G et al. Long-term beneficial effects of dexamethasone on intellectual and neuropsychological outcome of children with pneumococcal meningitis. Scand. J. Infect. Dis. 2006; 38(2): 104-109. Go to original source... Go to PubMed...
    13. Stephen I, Pelton, HH et al. Emergence of 19A as virulent and multidrug resistant pneumococcus Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007; 26(6): 468-472. Go to original source... Go to PubMed...
    14. Saha SK, Darmstadt GL et al. Rapid diagnosis of pneumococcal meningitis: implication of treatment and measuring disease burden. Pediatr.Infec Dis J. 2005; 24(12): 1093-1098. Go to original source... Go to PubMed...
    15. Serpil E, Alper E et al. Validation of urinary antigen test for Streptococcus pneumoniae in patients with pneumococcal pneumonia: Jpn. J. Infect. Dis., 2006; 59, 388-390.
    16. Simell B, Jaakkola T, Lahdenkari M etc. Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media: Clinical and Vaccine Imunology, 2006; 1177-1179. Go to original source... Go to PubMed...
    17. Simell B, Kilpi, T, Kahty H. Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysacharide of type 14 and pneumococcal surface adhesin A (PsaA) in children. British Society for Immunology, Clinical and Experimental Immunology, 2006; 143: 543-549. Go to original source... Go to PubMed...
    18. Urbánková R, Jakubů V, Žemličková H, Macková B a CZ-EARSS: Rezistence k antibiotikům u sedmi druhů invazivních bakterií, sledovaných v rámci EARSS v České republice v letech 2000-2006, Prakt. Lék., 2007; 87(1): 32-39.
    19. Wasier AP, Chevret L et al. Pneumococcal meningitis in pediatric intensive care unit: prognostic factors in a series of 49 children. Pediatr Crit Care Med. 2005; 6(5): 568-572. Go to original source... Go to PubMed...
    20. WHO, Geneva. Weekly epidemiological record. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper, 2007; 12: 93-104.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.